Pharmaceuticals
股价
$62.47
+1.56%市值
$125.88B
今日最高
$62.82
今日最低
$61.60
Bristol-Myers Squibb delivered Q1 2026 revenue of $11.49B (+2.6% YoY) and net income of $2.68B (+9.0% YoY), though operating cash flow fell sharply by 43.5% to $1.10B amid a 17.4% surge in R&D spending and elevated long-term debt of $44.1B.
关键风险:Heavy Debt Burden from Prior Acquisitions
BMY carries $44.14B in long-term debt and a debt-to-equity ratio of 3.31x, reflecting the legacy of large acquisitions such as Celgene. While deleveraging is underway, the elevated debt load constrains financial flexibility and increases vulnerability to interest rate changes or revenue shortfalls.
同属 Pharmaceuticals 行业的其他公司